These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32658035)

  • 41. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial.
    Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Salin L; Juhel N; Poewe W;
    Neurology; 2011 Aug; 77(8):767-74. PubMed ID: 21832216
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-acting versus standard non-ergot dopamine agonists in Parkinson's disease: a meta-analysis of randomized controlled trials.
    Zhou CQ; Lou JH; Zhang YP; Zhong L; Chen YL; Lu FJ; Peng GG
    CNS Neurosci Ther; 2014 Apr; 20(4):368-76. PubMed ID: 24588909
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dilemma in Parkinson's Treatment; Levodopa Monotherapy May be the Best Choice.
    Abbasi MH; Esmaeili S; Habibi SA; Shahidi GA
    J Clin Neurosci; 2020 Sep; 79():219-223. PubMed ID: 33070900
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pramipexole in patients with early Parkinson's disease.
    Hubble JP; Koller WC; Cutler NR; Sramek JJ; Friedman J; Goetz C; Ranhosky A; Korts D; Elvin A
    Clin Neuropharmacol; 1995 Aug; 18(4):338-47. PubMed ID: 8665547
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DA agonists -- non-ergot derivatives: piribedil: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S90-2. PubMed ID: 12211147
    [No Abstract]   [Full Text] [Related]  

  • 46. Peripheral edema and dopamine agonists in Parkinson disease.
    Tan EK
    Arch Neurol; 2007 Oct; 64(10):1546-7; author reply 1547. PubMed ID: 17923645
    [No Abstract]   [Full Text] [Related]  

  • 47. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group.
    Clin Neuropharmacol; 2000; 23(1):34-44. PubMed ID: 10682229
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rotigotine transdermal system for the treatment of Parkinson's disease.
    Pham DQ; Nogid A
    Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
    Olanow CW; Kieburtz K; Leinonen M; Elmer L; Giladi N; Hauser RA; Klepiskaya OS; Kreitzman DL; Lew MF; Russell DS; Kadosh S; Litman P; Friedman H; Linvah N; The P B Study Group F
    Mov Disord; 2017 May; 32(5):783-789. PubMed ID: 28370340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment of Parkinson's disease: use of piribedil].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(1):54-6. PubMed ID: 14870695
    [No Abstract]   [Full Text] [Related]  

  • 52. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.
    Márquez-Cruz M; Díaz-Martínez JP; Soto-Molina H; De Saráchaga AJ; Cervantes-Arriaga A; Llorens-Arenas R; Rodríguez-Violante M
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):97-102. PubMed ID: 26731410
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
    Zhuo C; Zhu X; Jiang R; Ji F; Su Z; Xue R; Zhou Y
    Sci Rep; 2017 Apr; 8():45865. PubMed ID: 28374775
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison.
    Li BD; Bi ZY; Liu JF; Si WJ; Shi QQ; Xue LP; Bai J
    CNS Neurosci Ther; 2017 Oct; 23(10):827-842. PubMed ID: 28872217
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sleep attacks and Parkinson's disease treatment.
    Ferreira JJ; Galitzky M; Montastruc JL; Rascol O
    Lancet; 2000 Apr; 355(9212):1333-4. PubMed ID: 10776750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group.
    Shannon KM; Bennett JP; Friedman JH
    Neurology; 1997 Sep; 49(3):724-8. PubMed ID: 9305331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
    Pinter MM; Rutgers AW; Hebenstreit E
    J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
    Lee JY; Jeon B; Koh SB; Yoon WT; Lee HW; Kwon OD; Kim JW; Kim JM; Ma HI; Kim HT; Baik JS; Cho J;
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):30-37. PubMed ID: 30361296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.